Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Separation of the combined Patient Monitoring and Respiratory Interventions businesses ("NewCo") expected to better position both NewCo and Medtronic for long-term success and value creation Enhances both Medtronic and NewCo's strategic and operational focus on meeting the needs of their respective patients, physicians, customers, and other stakeholders Advances the Medtronic portfolio management and capital allocation strategies focused on higher growth markets and revenue acceleration Pursuing NewCo separation via a distribution that is expected to be tax-free to Medtronic shareholders for U.S. federal income tax purposes or other alternatives DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its intention to pursue a separation of the company's combined Patient Monitoring and Respiratory Interventions businesses ("NewCo"), which are part of the company's Medical Surgical Portfolio. "We are executing on our portfolio management strategy, taking action to create value for Medtronic and our shareholders.

Medtronic announces intention to separate its combined Patient Monitoring and Respiratory Interventions businesses

Veeva Systems

Both have lagged the market in the past year.

2 Stocks to Buy and Forget in This Bear Market

NEW ORLEANS , Oct. 21, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 7, 2022 to file lead plaintiff applications in a securities class action lawsuit against Medtronic plc (NYSE: MDT), if they purchased the Company's shares between June 8, 2019, and May 25, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Minnesota.

MEDTRONIC HOLDINGS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Medtronic plc - MDT

Alibaba

These stocks may not stay this cheap for long.

Bear Market Bargains: 2 Stocks Near Multi-Year Lows That Are Red-Hot Buys

Hugo™ robotic-assisted surgery system regulatory approval in Japan provides access to third largest robotics market in the world while general surgery approval in the EU and Canada open fast-growing hernia specialty DUBLIN , Oct. 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global healthcare technology leader, has announced three significant global market-entrance and indication expansion approvals for its Hugo™ robotic-assisted surgery (RAS) system. The approvals include: Conformité Européenne (CE) Mark clearance for general surgery indication; Health Canada licence for general laparoscopic surgery indication; and Ministry of Health, Labor, and Welfare (MHLW) approval for urologic surgical and gynecologic laparoscopic indications in Japan.

Medtronic expands global access to the benefits of robotic-assisted surgery

DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Medtronic plc, the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data science to provide personalized tips, trends, and reminders that customers can use to help with their diabetes management goals.

Medtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes

Medtronic "Conduction System Pacing" Expanded Indication Now Includes Left Bundle Branch Area Pacing in Addition to His-Bundle Pacing for Patients with Slow Heart Rates DUBLIN , Oct. 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for expanded labeling of a cardiac lead that taps into the heart's natural electrical system, giving patients needed therapy while avoiding complications sometimes associated with traditional pacing methods, such as cardiomyopathy.1 Commonly referred to as "conduction system pacing," this approach helps ensure that pacing closely mimics the heart's physiologic contractions, allowing the heart's ventricles to work in coordination.1 Medtronic is the first and only company with therapies approved for conduction system pacing. In 2018, the FDA approved the SelectSecure™ MRI SureScan® Model 3830 cardiac lead for His-Bundle pacing, another form of conduction system pacing.

Medtronic First to Receive FDA Approval for Pacing the Heart's Natural Conduction System

DUBLIN , Oct. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the company will host a webcast to provide an update on its Medtronic Coronary and Renal Denervation business during the American Heart Association annual scientific sessions (AHA 2022) on Monday, November 7, 2022, at 5 p.m. CST. The webcast will feature remarks from Medtronic Coronary and Renal Denervation management, including comments on the 6-month results from the SPYRAL HTN-ON MED Randomized Trial (ON MED).

Medtronic to webcast renal denervation investor & analyst briefing on November 7

New York, New York--(Newsfile Corp. - October 13, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, A Top Ranked Law Firm, Encourages Medtronic plc Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - MDT

This is the second notable recognition the company has received this week, following being named to the Fortune 2022 'Change the World' list DUBLIN , Oct. 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Great Place to Work® and Fortune magazine have honored Medtronic as one of the 25 global companies named to the World's Best Workplaces™ in 2022. For more than six decades, the Medtronic Mission has served as a strategic framework for the company and guided its efforts to use technology to alleviate pain, restore health, and extend life.

Fortune and Great Place to Work® Name Medtronic one of the 'World's Best Workplaces™' in 2022

Teladoc

Oxford County Paramedic Services with the Oxford Ontario Health Team (OHT) purchases 160 additional Connected Health™ kits to meet growing demand for its Community Paramedicine Remote Care Monitoring program. News in Summary Oxford County Paramedic Services makes Connected Health™ kits available to vulnerable patients enrolled in their Community Paramedicine Program The Ontario Community Paramedicine for Long Term Care Program received $82 million in 2021 to provide seniors with extra care in their homes prior to admission to long term care.

Cloud DX Grows Paramedic Deployments with Oxford County ON

Archer-Daniels-Midland Company

BioNTech SE

EOG Resources

Pfizer

Stryker

Are you looking for a relatively safe mutual fund haven amid current market carnage? Check out Madison Covered Call & Equity Income Fund (MENYX).

Income Plus Low Volatility Makes This Fund A Safe Haven

"Engineering impact" highlights the Company's progress toward health equity, workforce diversity and net zero emissions DUBLIN , Oct. 11, 2022 /PRNewswire/ -- Medtronic plc today released its fiscal year (FY) 2022 Integrated Performance Report: Engineering impact. The report highlights the Company's progress on its ESG strategy, including measurable impact across patient access and equity; life-transforming healthcare technology; inclusion, diversity and equity (ID&E) and environmental sustainability.

Medtronic releases 2022 Integrated Performance Report

Abbott Labs

DexCom

These companies are three of the leading manufacturers of continuous glucose monitoring systems.

3 Diabetes Care Stocks That Could Help Set You Up for Life

Amcor Plc

Air Products and Chemicals

Franklin Resources

Essex Property Trust

Federal Realty Investment Trust

Coca-Cola

Leggett & Platt

Realty Income Corp

Stanley Black & Decker

T. Rowe Price Group

V.F.

Walgreens

"Dividend Aristocrats in the S&P 500 Index have raised their annual payouts every year for at least 25 consecutive years." - Kiplinger.com/Investing. 65 Aristocrats screened as of October 6, 2022 represented all eleven Morningstar Sectors. Broker estimated top-ten net gains ranged 24.27%-48.52% topped by VFC and SWK.

5 Top October Aristocrats, Which One To Buy?

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Medtronic Plc (""Medtronic" or the "Company") (NYSE: MDT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Medtronic and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Medtronic Plc - MDT

NEW YORK , Oct. 8, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline. SO WHAT: If you purchased Medtronic securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Medtronic plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MDT

New York, New York--(Newsfile Corp. - October 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, A LEADING LAW FIRM, Encourages Medtronic plc Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - MDT

New York, New York--(Newsfile Corp. - October 5, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, Top Ranked Investor Counsel, Encourages Medtronic plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - MDT

Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Here is What to Know Beyond Why Medtronic PLC (MDT) is a Trending Stock

Medtronic struggled to fill orders over the past year due to supply issues. As a result, the enterprise value of the company is near five-year lows.

Medtronic: Upgrading To Buy

New York, New York--(Newsfile Corp. - October 2, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Medtronic plc (NYSE: MDT) between June 8, 2019 and May 25, 2022, both dates inclusive (the "Class Period"), of the important November 7, 2022 lead plaintiff deadline.

ROSEN, A TOP RANKED FIRM, Encourages Medtronic plc Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - MDT

AstraZeneca

Elevance Health Inc

Humana

Sanofi

Inflation is easing, says a top thinker for BlackRock, the world's largest asset manager. But it's not falling to what Americans have grown used to.

BlackRock's DeSpirito: Brace For Stubborn Inflation

Aflac

Enbridge

Lowe's

Dividend champions are companies that have raised the dividend for 25 years. These are coveted by DGI investors because of the dividend safety they represent. Finding companies with long dividend growth histories, high initial yields, and a quickly growing dividend is the trifecta of dividend growth investing.

5 Dividend Champions With High Yields And High Growth

We believe Medtronic stock (NYSE: MDT) is currently a better pick than Johnson & Johnson stock (NYSE: JNJ), given its better prospects.

News for Medtronic Stock (MDT)